Jefferies Explains its Optimism for Enanta Pharmaceuticals (ENTA) RSV Trial

Jefferies analyst Akash Tewari reiterated a Buy rating and $105.00 price target on Enanta Pharmaceuticals (NASDAQ: ENTA) has two big shots on goal and low expectations due to the graveyard of failed antivirals over the last two decades. However, he thinks investors should look and sees a 50/50 chance of showing signal in the upcoming readout.

The analyst stated "We’re optimistic about RSVP given #1. EDP-938’s MOA (replication/N-inhibitor), which could translate to earlier onset of effect and lower risk for resistant strains, #2. RSVP’s aggressive early symptom cutoff of 2 days, as RSV trials w/ other cmpds support improved efficacy when treated earlier (including JNJ-678’s recent outpatient Ph.2a), #3. primary endpoint is total symptom score reduction (likely AUC) and symptom scores correlate well with viral load,"

For an analyst ratings summary and ratings history on Enanta Pharmaceuticals click here. For more ratings news on Enanta Pharmaceuticals click here.

Shares of Enanta Pharmaceuticals closed at $76.06 yesterday.

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald